Answers are grounded in this paper and cite their sources.
(See the Major Article by Cunningham et al., on pages 628–36.) In this issue of the Journal of Infectious Diseases, Cunningham et al [1] report the results of a small phase 1 safety and pharmacokinetics clinical trial of the anti-human immunodeficiency virus (HIV) antibody VRC01 in exposed infants. The introduction of antiretroviral therapy (ART) for the prevention of mother-to-child transmission (MTCT) was an important turning point that resulted in a steep decrease of pediatric HIV infections in the last decade. Despite this significant public health achievement, MTCT remains a challenge. In 2017, an estimated 1.4 million pregnant women were living with HIV, and approximately 500 new HIV infections occurred daily among children under the age of 4 [2], which highlights the need for novel interventions. Highly potent broadly neutralizing anti-HIV antibodies (bNAbs) have shown their therapeutic potential during HIV infection [3–6] and might be a novel immunoprophylactic tool to advance the prevention and potential elimination of MTCT. Although VRC01, a CD4 binding site-specific antibody [7], has previously been evaluated and shown to be safe and well tolerated in adults [8], the study by Cunningham et al [1] is the first clinical report of a bNAb intervention in children of any age. A single subcutaneous dose of VRC01 was administered in combination with standard antiretroviral prophylaxis to formula-fed and as multiple doses to breastfeeding HIV-exposed infants and shown to be safe and well tolerated. Vertical HIV transmission through breastfeeding in the postnatal period continues to be a significant problem because it contributes to approximately half of the overall MTCT risk [9, 10]. Although breastfeeding in the first months reduces morbidity and all-cause mortality in children younger than 5 years [11], breastmilk can transmit HIV and exposes infants to a potential source of infection for long periods of time [12]. As a result, without prophylactic interventions, the rate of breastmilk viral transmission is estimated to be 0.74% per month of breastfeeding [13]. Child-feeding recommendations recognize the benefits and risks of breastfeeding and differ depending on access to formula and safe drinking water. Although high-income countries advise exclusive formula feeding, in low- and middle-income countries breastfeeding with maternal ART is the recommended approach [14]. The mechanistic understanding of breastmilk viral transmission is limited. Known major risk factors for vertical transmission are cell-free and cell-associated viral load levels in blood and breastmilk. Accordingly, new onset HIV infections in mothers while breastfeeding increase the risk of MTCT to approximately 30% [15]. An increased vulnerability of the infant due to enhanced intestinal permeability, relative achlorhydria, as well as large population of intestinal CCR5+ memory CD4 T cells and immature viral immunity may facilitate passage of cell-free and cell-associated viruses from breastmilk and ultimately result in viral transmission [12]. Although the broader implementation of ART among pregnant women living with HIV decreased vertical transmission substantially, poor retention in routine care and insufficient maternal ART adherence are continuing obstacles for the elimination of MTCT. Moreover, the now established U=U (undetectable = untransmittable) concept—meaning that individuals with undetectable plasma viral loads cannot sexually transmit HIV to others—does not readily apply to breastmilk viral transmission [16]. Even with undetectable plasma HIV ribonucleic acid levels, residual breastmilk infectivity through local HIV reactivation during mammary gland infections and breastmilk transmission through activated latent CD4+ T cells seem possible [10, 17]. Antiretroviral drug exposure of breastfed infants is an additional difficulty. For example, breastmilk ART exposure in infants can impede viral detection by polymerase chain reaction and interfere with the timely and accurate diagnosis of HIV transmission. In addition, toxic effects of infant exposure to ART and the risk of drug resistance among infants who acquire HIV are possible complications [12]. These challenges, taken together, expose an unmet medical need and support the evaluation of bNAb passive immunoprophylaxis for prevention of MTCT in HIV-exposed infants. The study by Cunningham et al [1] shows that VRC01 as single or multiple doses is safe in newborn infants. Adverse events were mild to moderate and mostly limited to local reactions. Although no systemic reactions occurred among infants receiving a single dose of VRC01, grade 1 systemic reactions such as fever, irritability, and appetite decrease were observed shortly after antibody administration in 4 infants receiving multiple antibody doses. These results are promising, especially because this is the first bNAb intervention in children of any age. This first study did not include an assessment of unwanted immunogenicity, eg, antidrug antibodies. Although antidrug antibody responses have not been reported in VRC01 studies in adults, if induced, such responses could potentially interfere with the safety profile and overall efficacy of this immunoprophylactic approach. Based on in vitro neutralization studies of VRC01, the authors determined a target serum concentration of 50 µg/mL at 4 weeks after dosing. All but 1 participant who received 40 mg/kg of VRC01, and all participants receiving multiple doses, maintained serum levels above the target concentration after 4 weeks or throughout breastfeeding, respectively. It is interesting to note that no vertical transmission among the 40 participants was observed, although a formal evaluation of the prophylactic efficacy will require a larger sample size and the use of standard of care ART prophylaxis. Looking ahead, VRC01 alone may not provide sufficient potency and breadth to demonstrate clear efficacy [7]. Newer generation bNAbs, as single or combination therapy, could achieve adequate coverage with high potency against diverse circulating viral strains [3–5, 18]. In addition, long-acting bNAbs demonstrate remarkably increased half-lives, making them attractive candidates for use in prevention of MTCT where long-term protection after a single dose could circumvent inadequate retention in care [19]. Comparative phase 1 clinical trials of VRC01 and its modified long-acting version and a more potent engineered antibody, VRC01LS and VRC07-523LS, are currently ongoing in HIV-exposed infants (NCT02256631). Other areas that could be explored in future studies include maternal bNAb immunoprophylaxis as an additional strategy for prevention of MTCT, as well as the potential impact of bNAbs on the CD4+ T cell-associated HIV reservoir in breast milk [10, 20, 21]. Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
No takes yet. Share an insight, caveat, or question.
Gaebler et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: